Clinical Trial Search

Primary: Participants' Overall Satisfaction With the Drug Administration Experience Using the Physiolis Syringe/Autoinjector in Comparison to the Current Syringe/Autoinjector…

Primary: Mean Change From Baseline in Evaporative Air Sensitivity Pain Response on a Schiff Sensitivity Scale at Week 8 — -0.9; -0.5 Score on a scale — p=<0.0001

Primary: Change From Randomization to End of Treatment in Scores on the Hamilton Anxiety Rating Scale (HAM-A) — 21.23 scores on an anxiety scale

Primary: Overall Survival (OS) — 11.17; 9.07 Months — p=0.0009

Primary: Safety and Tolerability of Dalfampridine-ER in Subjects With Chronic Deficits After Ischemic Stroke Assessed by Number of Treatment Emergent Adverse Events (TEAEs) — 30…

Primary: Incidence of Nosocomial Infections in the Cardiac ICU — 8.6; 9.9 infections / 1000 pt days

Primary: Geometric Mean antiHAV and antiHBV Concentrations (GMCs), 28 Days After Primary and Booster Vaccination — 48; 30; 786; 884 Concentrations (mIU/mL)

Primary: Morphine Consumption — 48.75; 10 mg

Primary: Cathelicidin mRNA Expression Levels in Adult Skin From Patients With AD — .0016; .0024 delta-delta ct units on PCR

Primary: Leakage Under the Base Plate Using a 24-point Scale — 4.5; 3.3; 4.4 units on a scale

Primary: Percentage of Responders as Defined by Single Nucleotide Polymorphism (SNP) Markers — 63.5; 63.9; 65.6; 60.3 percentage of participants

Primary: Time to First On-Study Skeletal Related Event (SRE) (Non-inferiority) — 372; 315 Participants — p=<0.0001

Primary: Impact of Event Scale-Revised — 26.00; 19.10; 14.11 units on a scale — p==.068

Primary: Working Memory — 0.86; 0.04 digits recalled

Primary: Response at Week 12 as Assessed by Randomized Tool [Clinical Disease Activity Index (CDAI) or Routine Assessment of Patient Index Data 3 (RAPID3)] — 64.7; 76.4; 35.3…